# Astellas Pharma

Astellas Pharma is an Asset Manager based in Tokyo, Japan.

## Overview

- **Organization type:** Asset Manager
- **Headquarters:** Tokyo, Japan
- **Region:** Asia
- **Address:** Tokyo, Japan
- **Founded:** 2005
- **Assets under management:** Undisclosed
- **Website:** astellas.com

## Regulatory record

- **Reports private funds:** No

## About

Astellas is a global life sciences company turning science into value for patients through transformative therapies. Discover how we're pioneering new healthcare solutions.

## Sectors

- Oncology
- Ophthalmology
- Urology
- Immunology
- Women's Health

## Offices

- Basel, Switzerland
- San Francisco, CA, United States
- Hellerup, Denmark

## People

- Naoki Okamura — Representative Director, President and CEO

## Questions

### Who runs investment and strategic decisions at Astellas Pharma?

Naoki Okamura, Representative Director, President and CEO, guides Astellas's five-year Corporate Strategic Plan (CSP2026). The plan governs R&D focus, therapeutic-area selection, and capital allocation. Astellas's board and top management set investment posture as detailed in the annual Integrated Report.

### How does Astellas source innovation beyond its internal pipeline?

Astellas runs an open-innovation network called SakuLab with wet-lab sites in Tsukuba and Cambridge. The firm also operates the TME iLab for tumor-microenvironment research and a digital-health Rx+ Business Accelerator. These hubs complement internal drug-discovery capabilities and clinical-stage partnerships.

### Which therapeutic areas does Astellas prioritize for deployment?

Astellas concentrates on five areas: oncology, ophthalmology, urology, immunology, and women's health. Its R&D pipeline further focuses on blindness and regeneration, genetic regulation, immuno-oncology, and targeted protein degradation.

### How does Astellas's five-year strategic plan influence capital allocation?

CSP2026 structures resource allocation around pipeline milestones, therapeutic focus areas, and digital-transformation goals. The plan aims to position Astellas as a sustainable growth company and ties non-financial metrics — such as AI-enhanced drug discovery — directly to investment decisions.

### What distinguishes Astellas structurally from other global pharma firms?

Its distributed R&D model pairs internal discovery engines with SakuLab open-innovation sites and digital-health accelerators like HealthX. This architecture enables simultaneous push into targeted protein degradation, gene therapy, and AI-driven drug design, governed by a five-year strategic cycle.

## Related profiles

- [Corteva Agriscience](https://altss.com/profile/corteva-agriscience)
- [TA Realty](https://altss.com/profile/ta-realty)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/astellas-pharma-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology